Home » Stocks » Pluristem Therapeutics

Pluristem Therapeutics, Inc. (PSTI)

Stock Price: $9.10 USD -0.79 (-7.99%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
After-hours: $9.20 +0.10 (1.10%) Aug 6, 4:57 PM

Stock Price Chart

Key Info

Market Cap 231.98M
Revenue (ttm) 23,000
Net Income (ttm) -28.78M
Shares Out 25.49M
EPS (ttm) -1.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $9.10
Previous Close $9.89
Change ($) -0.79
Change (%) -7.99%
Day's Open 9.72
Day's Range 9.10 - 9.73
Day's Volume 537,227
52-Week Range 2.82 - 13.29

More Stats

Market Cap 231.98M
Enterprise Value 218.28M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.49M
Float 20.13M
EPS (basic) -1.78
EPS (diluted) -1.80
FCF / Share -1.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 930,770
Short Ratio 2.08
Short % of Float 3.92%
Beta 2.60
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 10,086.24
PB Ratio 17.63
Revenue 23,000
Operating Income -28.89M
Net Income -28.78M
Free Cash Flow -26.90M
Net Cash 13.70M
Net Cash / Share 0.54
Gross Margin 226.09%
Operating Margin -125,621.74%
Profit Margin -125,113.00%
FCF Margin -116,952.17%
ROA -86.50%
ROE -252.46%
ROIC -198.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$16.10*
(76.92% upside)
Low
12.0
Current: $9.10
High
25.0
Target: 16.10
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.050.05-2.850.380.380.680.72--
Revenue Growth8%--651.19%0%-44.18%-5.17%---
Gross Profit0.050.05-2.750.370.370.660.70--
Operating Income-35.53-33.73-28.02-23.32-25.27-27.85-22.22-15.03-11.11-7.44
Net Income-35.31-26.13-27.81-23.25-24.68-26.93-21.16-14.79-10.85-7.45
Shares Outstanding12.3310.598.747.957.036.355.554.403.121.70
Earnings Per Share-2.90-2.50-3.20-2.90-3.50-4.20-3.80-3.40-3.50-4.40
Operating Cash Flow-29.45-21.38-21.61-18.52-20.61-19.12-16.89-3.28-5.76-5.41
Capital Expenditures-0.24-0.34-0.35-1.72-0.81-1.57-4.31-1.48-0.93-0.39
Free Cash Flow-29.69-21.72-21.96-20.24-21.42-20.69-21.20-4.76-6.69-5.80
Cash & Equivalents24.4030.5926.6732.7553.1258.8254.2137.8142.832.50
Net Cash / Debt24.4030.5926.6732.7553.1258.8254.2137.8142.832.50
Assets31.3138.9637.5345.9468.1674.0268.3247.4246.025.62
Liabilities9.4910.457.287.7910.0111.9010.859.682.591.64
Book Value21.8228.5130.2538.1658.1462.1257.4737.7443.423.98
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pluristem Therapeutics, Inc.
Country Israel
Employees 160
CEO Yaky Yanay

Stock Information

Ticker Symbol PSTI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PSTI

Description

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.